XERS.Q

Xeris Pharmaceuticals (XERS.Q) announces today that the U.S. Food and Drug Administration (FDA) has allowed the Investigational New Drug Application (IND) for the Company’s XeriSol™ levothyroxine (XP-8121) for hypothyroidism…